{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'development of a cutaneous reaction during treatment warrants prompt evaluation by the', 'Investigator or designee.', 'Photosensitivity reactions may occur hours to days after sun exposure. Patients should be', 'advised to avoid direct and indirect sun exposure as much as possible from Cycle 1 Day 1', 'until 30 days after the final dose. When sun exposure is unavoidable, patients should', 'wear protective clothing and sunglasses, and use a broad-spectrum sunscreen and lip balm', '(SPF 30 or greater). Thirty-one to ninety days after last dose of Rova-T/placebo, the', 'patient may resume outdoor activities with appropriate sun protection including broad', 'brimmed hat, protective clothing and sunscreen SPF 30 or higher. Subjects with a grade 3', 'photosensitivity reaction should dose reduce Rova-T/placebo to 0.2 mg/kg after the first', 'occurrence and following a second grade 3 photosensitivity reaction, reduce Rova-', 'T/placebo to 0.1 mg/kg. Subjects with a grade 4 photosensitivity reaction must', 'permanently discontinue Rova-T/placebo.', 'If clinically consistent with photosensitivity, the AE should be reported as such (using', 'medically accurate and descriptive AE terminology), and managed as described in', 'Table 6.', 'Photo-documentation of skin toxicity should be available upon request by the TA MD.', 'The investigative site will take measures to protect the identity of the patient. These', 'measures include taking the photograph very close to the affected skin region to exclude', 'facial features, or if facial features cannot be excluded due to the location of the skin', 'reaction, covering identifying features (such as the eyes) with a black rectangle.', 'Formal evaluation by a dermatologist, including possible skin biopsy to rule out', 'alternative etiologies such as erythema multiforme, which may warrant discontinuation of', 'blinded investigational product, and to facilitate the most appropriate terminology for AE', 'reporting.', 'All events of cutaneous toxicity should be monitored until resolution or return to baseline.', 'Recommendations for management of photosensitivity reactions are outlined in Table 6.', '86']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Table 6.', 'Recommended Management of Photosensitivity', 'CTCAE v4.0', 'Treatment Recommendations', 'Dose Modifications', 'Grade 1', 'Painless erythema and', 'Low-potency topical steroid (face)', '-', 'erythema covering < 10% BSA', 'High-potency topical steroid', '(body)', 'Grade 2', 'Tender erythema covering 10 - Low-potency topical steroid (face)', '-', '30% BSA', 'High-potency topical steroid', '(body)', 'Nonsteroidal anti-inflammatory', 'agents orally as needed', 'Grade 3', 'Erythema covering > 30%', 'Low-potency topical steroid (face)', 'Reduce dose', 'BSA and erythema with', 'High-potency topical steroid', 'blistering; photosensitivity;', '(body)', 'oral corticosteroid therapy', 'Prednisone 0.5 mg/kg X 7 days', 'indicated; pain control', 'indicated (e.g., narcotics or', 'NSAIDs)', 'Grade 4', 'Life-threatening consequences;', 'Low-potency topical steroid (face)', 'Discontinue', 'urgent intervention indicated', 'High-potency topical steroid', '(body)', 'Prednisone 0.5 mg/kg X 7 days', 'Hospitalization', 'In order to simplify the collection of detailed Safety Data associated with dermatological', 'issues, prior to the verification of a specific diagnosis the general term of \"Skin Toxicity\"', 'should be recorded on the Adverse Event eCRF and the corresponding details should be', 'captured on the Skin Toxicity Supplemental eCRF (as outlined in the form). Once a final', 'dermatological diagnosis is verified, the AE eCRF should be updated to reflect the', 'specific diagnosis.', '6.1.8.3', 'Management of Potential Drug-Induced Liver Injury', 'Wherever possible, timely confirmation of initial liver-related laboratory abnormalities', 'should occur prior to the reporting of a potential drug-induced liver injury (DILI) event.', 'All occurrences of potential DILIs, meeting the defined criteria, must be reported as', 'SAEs.', '87']\n\n###\n\n", "completion": "END"}